| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w20867 |
| 来源ID | Working Paper 20867 |
| Pricing in the Market for Anticancer Drugs | |
| David H. Howard; Peter B. Bach; Ernst R. Berndt; Rena M. Conti | |
| 发表日期 | 2015-01-19 |
| 出版年 | 2015 |
| 语种 | 英语 |
| 摘要 | Drugs like bevacizumab ($50,000 per treatment episode) and ipilimumab ($120,000 per episode) have fueled the perception that the launch prices of anticancer drugs are increasing over time. Using an original dataset of 58 anticancer drugs approved between 1995 and 2013, we find that launch prices, adjusted for inflation and drugs’ survival benefits, increased by 10%, or about $8,500, per year. Although physicians are not penalized for prescribing costly drugs, they may be reluctant to prescribe drugs with prices that exceed subjective standards of fairness. Manufacturers may set higher launch prices over time as standards evolve. Pricing trends may also reflect manufacturers’ response to expansions in the 340B Drug Pricing Program, which requires manufacturers to provide steep discounts to eligible providers. |
| 主题 | Health, Education, and Welfare ; Health |
| URL | https://www.nber.org/papers/w20867 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/578542 |
| 推荐引用方式 GB/T 7714 | David H. Howard,Peter B. Bach,Ernst R. Berndt,et al. Pricing in the Market for Anticancer Drugs. 2015. |
| 条目包含的文件 | 条目无相关文件。 | |||||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
